ChloroquineV1, PascalFrancis, Corpus, bibRecord, 000011

Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry

Identifieur interne : 000011 ( PascalFrancis/Corpus ); précédent : 000010; suivant : 000012

Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry

Auteurs : Ling-Zhi Wang ; Rina Yue-Ling Ong ; Tan-Min Chin ; Win-Lwin Thuya ; Seow-Ching Wan ; Andrea Li-Ann Wong ; Sui-Yung Chan ; Paul C. Ho ; Boon-Cher Goh

Source :

Journal of pharmaceutical and biomedical analysis [ 0731-7085 ] ; 2012.

RBID : Pascal:12-0147418

Descripteurs français

Pascal (Inist)
- Développement, Validation, Analyse quantitative, Hydroxychloroquine, Homme, Liquide biologique, Sang, Chromatographie HPLC, Spectrométrie masse tandem, Antiparasitaire, Antipaludique, Antirhumatismal, LC MS MS.

English descriptors

KwdEn :
- Antimalarial, Antirheumatic agent, Biological fluid, Blood, Development, HPLC chromatography, Human, Hydroxychloroquine, Mass spectrometry MS/MS, Parasiticide, Quantitative analysis, Validation.

Abstract

A novel and specific liquid chromatography-tandem mass spectrometric method (LC-MS/MS) was developed and validated for the quantification of hydroxychloroquine in human blood using its stable labeled isotope, hydroxychloroquine-d4 as the internal standard. Chromatographic separation of analytes was achieved using an Agilent ZORBAX Eclipse XDB - C8 analytical HPLC column (50 mm x 2.1 mm, 5 μm). The mobile phase comprising water containing 0.1% formic acid-acetonitrile (94:6, v/v) was delivered isocratically at a flow rate of 0.5 mL/min. The column effluent was detected by API 4000 triple quadrupole mass spectrometer using electrospray ionization (ESI) and monitored by multiple reaction monitoring with positive mode. The precursor to product ion transitions of m/z 336 → 247 and m/z 340 → 251 were used to measure the analyte and IS, respectively. The assay demonstrated a good linear dynamic range of 5-2000 ng/mL for hydroxychloroquine in human blood, with coefficient of determination (r²) of =0.9999. The values for intra-day and inter-day precisions of hydroxychloroquine were ≤7.86% with the accuracies ranged from 93.8% to 107.6%. The chromatographic run time was 3 min, making it possible to achieve a high throughput analysis. This method was used as a bio-analytical tool in a phase 1 clinical trial to quantify blood hydroxychloroquine concentrations in patients with non-small cell lung cancer receiving both hydroxychloroquine and gefitinib in their treatment.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0731-7085`
A02	`01`			`@0 JPBADA`
A03		`1`		`@0 J. pharm. biomed. anal.`
A05				`@2 61`
A08	`01`	`1`	`ENG`	`@1 Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry`
A11	`01`	`1`		`@1 WANG (Ling-Zhi)`
A11	`02`	`1`		`@1 ONG (Rina Yue-Ling)`
A11	`03`	`1`		`@1 CHIN (Tan-Min)`
A11	`04`	`1`		`@1 THUYA (Win-Lwin)`
A11	`05`	`1`		`@1 WAN (Seow-Ching)`
A11	`06`	`1`		`@1 WONG (Andrea Li-Ann)`
A11	`07`	`1`		`@1 CHAN (Sui-Yung)`
A11	`08`	`1`		`@1 HO (Paul C.)`
A11	`09`	`1`		`@1 GOH (Boon-Cher)`
A14	`01`			`@1 Cancer Science Institute of Singapore, National University of Singapore @3 SGP @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 9 aut.`
A14	`02`			`@1 Department of Pharmacy, National University of Singapore @3 SGP @Z 2 aut. @Z 7 aut. @Z 8 aut.`
A14	`03`			`@1 Department of Haematology & Oncology, The National University Health System @3 SGP @Z 3 aut. @Z 6 aut. @Z 9 aut.`
A20				`@1 86-92`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 19962 @5 354000508487210130`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 25 ref.`
A47	`01`	`1`		`@0 12-0147418`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of pharmaceutical and biomedical analysis`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 A novel and specific liquid chromatography-tandem mass spectrometric method (LC-MS/MS) was developed and validated for the quantification of hydroxychloroquine in human blood using its stable labeled isotope, hydroxychloroquine-d4 as the internal standard. Chromatographic separation of analytes was achieved using an Agilent ZORBAX Eclipse XDB - C8 analytical HPLC column (50 mm x 2.1 mm, 5 μm). The mobile phase comprising water containing 0.1% formic acid-acetonitrile (94:6, v/v) was delivered isocratically at a flow rate of 0.5 mL/min. The column effluent was detected by API 4000 triple quadrupole mass spectrometer using electrospray ionization (ESI) and monitored by multiple reaction monitoring with positive mode. The precursor to product ion transitions of m/z 336 → 247 and m/z 340 → 251 were used to measure the analyte and IS, respectively. The assay demonstrated a good linear dynamic range of 5-2000 ng/mL for hydroxychloroquine in human blood, with coefficient of determination (r²) of =0.9999. The values for intra-day and inter-day precisions of hydroxychloroquine were ≤7.86% with the accuracies ranged from 93.8% to 107.6%. The chromatographic run time was 3 min, making it possible to achieve a high throughput analysis. This method was used as a bio-analytical tool in a phase 1 clinical trial to quantify blood hydroxychloroquine concentrations in patients with non-small cell lung cancer receiving both hydroxychloroquine and gefitinib in their treatment.
C02	`01`	`X`		`@0 002B02A02`
C02	`02`	`X`		`@0 002A02`
C03	`01`	`X`	`FRE`	`@0 Développement @5 01`
C03	`01`	`X`	`ENG`	`@0 Development @5 01`
C03	`01`	`X`	`SPA`	`@0 Desarrollo @5 01`
C03	`02`	`X`	`FRE`	`@0 Validation @5 02`
C03	`02`	`X`	`ENG`	`@0 Validation @5 02`
C03	`02`	`X`	`SPA`	`@0 Validación @5 02`
C03	`03`	`X`	`FRE`	`@0 Analyse quantitative @5 03`
C03	`03`	`X`	`ENG`	`@0 Quantitative analysis @5 03`
C03	`03`	`X`	`SPA`	`@0 Análisis cuantitativo @5 03`
C03	`04`	`X`	`FRE`	`@0 Hydroxychloroquine @2 NK @2 FR @5 04`
C03	`04`	`X`	`ENG`	`@0 Hydroxychloroquine @2 NK @2 FR @5 04`
C03	`04`	`X`	`SPA`	`@0 Hidroxicloroquina @2 NK @2 FR @5 04`
C03	`05`	`X`	`FRE`	`@0 Homme @5 05`
C03	`05`	`X`	`ENG`	`@0 Human @5 05`
C03	`05`	`X`	`SPA`	`@0 Hombre @5 05`
C03	`06`	`X`	`FRE`	`@0 Liquide biologique @5 06`
C03	`06`	`X`	`ENG`	`@0 Biological fluid @5 06`
C03	`06`	`X`	`SPA`	`@0 Líquido biológico @5 06`
C03	`07`	`X`	`FRE`	`@0 Sang @5 07`
C03	`07`	`X`	`ENG`	`@0 Blood @5 07`
C03	`07`	`X`	`SPA`	`@0 Sangre @5 07`
C03	`08`	`X`	`FRE`	`@0 Chromatographie HPLC @5 08`
C03	`08`	`X`	`ENG`	`@0 HPLC chromatography @5 08`
C03	`08`	`X`	`SPA`	`@0 Cromatografía HPLC @5 08`
C03	`09`	`X`	`FRE`	`@0 Spectrométrie masse tandem @5 09`
C03	`09`	`X`	`ENG`	`@0 Mass spectrometry MS/MS @5 09`
C03	`09`	`X`	`SPA`	`@0 Espectrometría masa en tándem @5 09`
C03	`10`	`X`	`FRE`	`@0 Antiparasitaire @5 23`
C03	`10`	`X`	`ENG`	`@0 Parasiticide @5 23`
C03	`10`	`X`	`SPA`	`@0 Antiparasitario @5 23`
C03	`11`	`X`	`FRE`	`@0 Antipaludique @5 24`
C03	`11`	`X`	`ENG`	`@0 Antimalarial @5 24`
C03	`11`	`X`	`SPA`	`@0 Antipalúdico @5 24`
C03	`12`	`X`	`FRE`	`@0 Antirhumatismal @5 25`
C03	`12`	`X`	`ENG`	`@0 Antirheumatic agent @5 25`
C03	`12`	`X`	`SPA`	`@0 Antireumático @5 25`
C03	`13`	`X`	`FRE`	`@0 LC MS MS @4 INC @5 86`
N21				`@1 114`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 12-0147418 INIST
ET :	Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry
AU :	WANG (Ling-Zhi); ONG (Rina Yue-Ling); CHIN (Tan-Min); THUYA (Win-Lwin); WAN (Seow-Ching); WONG (Andrea Li-Ann); CHAN (Sui-Yung); HO (Paul C.); GOH (Boon-Cher)
AF :	Cancer Science Institute of Singapore, National University of Singapore/Singapour (1 aut., 3 aut., 4 aut., 5 aut., 9 aut.); Department of Pharmacy, National University of Singapore/Singapour (2 aut., 7 aut., 8 aut.); Department of Haematology & Oncology, The National University Health System/Singapour (3 aut., 6 aut., 9 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of pharmaceutical and biomedical analysis; ISSN 0731-7085; Coden JPBADA; Pays-Bas; Da. 2012; Vol. 61; Pp. 86-92; Bibl. 25 ref.
LA :	Anglais
EA :	A novel and specific liquid chromatography-tandem mass spectrometric method (LC-MS/MS) was developed and validated for the quantification of hydroxychloroquine in human blood using its stable labeled isotope, hydroxychloroquine-d4 as the internal standard. Chromatographic separation of analytes was achieved using an Agilent ZORBAX Eclipse XDB - C8 analytical HPLC column (50 mm x 2.1 mm, 5 μm). The mobile phase comprising water containing 0.1% formic acid-acetonitrile (94:6, v/v) was delivered isocratically at a flow rate of 0.5 mL/min. The column effluent was detected by API 4000 triple quadrupole mass spectrometer using electrospray ionization (ESI) and monitored by multiple reaction monitoring with positive mode. The precursor to product ion transitions of m/z 336 → 247 and m/z 340 → 251 were used to measure the analyte and IS, respectively. The assay demonstrated a good linear dynamic range of 5-2000 ng/mL for hydroxychloroquine in human blood, with coefficient of determination (r²) of =0.9999. The values for intra-day and inter-day precisions of hydroxychloroquine were ≤7.86% with the accuracies ranged from 93.8% to 107.6%. The chromatographic run time was 3 min, making it possible to achieve a high throughput analysis. This method was used as a bio-analytical tool in a phase 1 clinical trial to quantify blood hydroxychloroquine concentrations in patients with non-small cell lung cancer receiving both hydroxychloroquine and gefitinib in their treatment.
CC :	002B02A02; 002A02
FD :	Développement; Validation; Analyse quantitative; Hydroxychloroquine; Homme; Liquide biologique; Sang; Chromatographie HPLC; Spectrométrie masse tandem; Antiparasitaire; Antipaludique; Antirhumatismal; LC MS MS
ED :	Development; Validation; Quantitative analysis; Hydroxychloroquine; Human; Biological fluid; Blood; HPLC chromatography; Mass spectrometry MS/MS; Parasiticide; Antimalarial; Antirheumatic agent
SD :	Desarrollo; Validación; Análisis cuantitativo; Hidroxicloroquina; Hombre; Líquido biológico; Sangre; Cromatografía HPLC; Espectrometría masa en tándem; Antiparasitario; Antipalúdico; Antireumático
LO :	INIST-19962.354000508487210130
ID :	12-0147418

Links to Exploration step

Pascal:12-0147418

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry</title>
<author><name sortKey="Wang, Ling Zhi" sort="Wang, Ling Zhi" uniqKey="Wang L" first="Ling-Zhi" last="Wang">Ling-Zhi Wang</name>
<affiliation><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ong, Rina Yue Ling" sort="Ong, Rina Yue Ling" uniqKey="Ong R" first="Rina Yue-Ling" last="Ong">Rina Yue-Ling Ong</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chin, Tan Min" sort="Chin, Tan Min" uniqKey="Chin T" first="Tan-Min" last="Chin">Tan-Min Chin</name>
<affiliation><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Haematology & Oncology, The National University Health System</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thuya, Win Lwin" sort="Thuya, Win Lwin" uniqKey="Thuya W" first="Win-Lwin" last="Thuya">Win-Lwin Thuya</name>
<affiliation><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wan, Seow Ching" sort="Wan, Seow Ching" uniqKey="Wan S" first="Seow-Ching" last="Wan">Seow-Ching Wan</name>
<affiliation><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wong, Andrea Li Ann" sort="Wong, Andrea Li Ann" uniqKey="Wong A" first="Andrea Li-Ann" last="Wong">Andrea Li-Ann Wong</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Haematology & Oncology, The National University Health System</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, Sui Yung" sort="Chan, Sui Yung" uniqKey="Chan S" first="Sui-Yung" last="Chan">Sui-Yung Chan</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ho, Paul C" sort="Ho, Paul C" uniqKey="Ho P" first="Paul C." last="Ho">Paul C. Ho</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Goh, Boon Cher" sort="Goh, Boon Cher" uniqKey="Goh B" first="Boon-Cher" last="Goh">Boon-Cher Goh</name>
<affiliation><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Haematology & Oncology, The National University Health System</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0147418</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0147418 INIST</idno>
<idno type="RBID">Pascal:12-0147418</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000011</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry</title>
<author><name sortKey="Wang, Ling Zhi" sort="Wang, Ling Zhi" uniqKey="Wang L" first="Ling-Zhi" last="Wang">Ling-Zhi Wang</name>
<affiliation><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ong, Rina Yue Ling" sort="Ong, Rina Yue Ling" uniqKey="Ong R" first="Rina Yue-Ling" last="Ong">Rina Yue-Ling Ong</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chin, Tan Min" sort="Chin, Tan Min" uniqKey="Chin T" first="Tan-Min" last="Chin">Tan-Min Chin</name>
<affiliation><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Haematology & Oncology, The National University Health System</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thuya, Win Lwin" sort="Thuya, Win Lwin" uniqKey="Thuya W" first="Win-Lwin" last="Thuya">Win-Lwin Thuya</name>
<affiliation><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wan, Seow Ching" sort="Wan, Seow Ching" uniqKey="Wan S" first="Seow-Ching" last="Wan">Seow-Ching Wan</name>
<affiliation><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wong, Andrea Li Ann" sort="Wong, Andrea Li Ann" uniqKey="Wong A" first="Andrea Li-Ann" last="Wong">Andrea Li-Ann Wong</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Haematology & Oncology, The National University Health System</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, Sui Yung" sort="Chan, Sui Yung" uniqKey="Chan S" first="Sui-Yung" last="Chan">Sui-Yung Chan</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ho, Paul C" sort="Ho, Paul C" uniqKey="Ho P" first="Paul C." last="Ho">Paul C. Ho</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Goh, Boon Cher" sort="Goh, Boon Cher" uniqKey="Goh B" first="Boon-Cher" last="Goh">Boon-Cher Goh</name>
<affiliation><inist:fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Haematology & Oncology, The National University Health System</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of pharmaceutical and biomedical analysis</title>
<title level="j" type="abbreviated">J. pharm. biomed. anal.</title>
<idno type="ISSN">0731-7085</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of pharmaceutical and biomedical analysis</title>
<title level="j" type="abbreviated">J. pharm. biomed. anal.</title>
<idno type="ISSN">0731-7085</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antimalarial</term>
<term>Antirheumatic agent</term>
<term>Biological fluid</term>
<term>Blood</term>
<term>Development</term>
<term>HPLC chromatography</term>
<term>Human</term>
<term>Hydroxychloroquine</term>
<term>Mass spectrometry MS/MS</term>
<term>Parasiticide</term>
<term>Quantitative analysis</term>
<term>Validation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Développement</term>
<term>Validation</term>
<term>Analyse quantitative</term>
<term>Hydroxychloroquine</term>
<term>Homme</term>
<term>Liquide biologique</term>
<term>Sang</term>
<term>Chromatographie HPLC</term>
<term>Spectrométrie masse tandem</term>
<term>Antiparasitaire</term>
<term>Antipaludique</term>
<term>Antirhumatismal</term>
<term>LC MS MS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A novel and specific liquid chromatography-tandem mass spectrometric method (LC-MS/MS) was developed and validated for the quantification of hydroxychloroquine in human blood using its stable labeled isotope, hydroxychloroquine-d4 as the internal standard. Chromatographic separation of analytes was achieved using an Agilent ZORBAX Eclipse XDB - C8 analytical HPLC column (50 mm x 2.1 mm, 5 μm). The mobile phase comprising water containing 0.1% formic acid-acetonitrile (94:6, v/v) was delivered isocratically at a flow rate of 0.5 mL/min. The column effluent was detected by API 4000 triple quadrupole mass spectrometer using electrospray ionization (ESI) and monitored by multiple reaction monitoring with positive mode. The precursor to product ion transitions of m/z 336 → 247 and m/z 340 → 251 were used to measure the analyte and IS, respectively. The assay demonstrated a good linear dynamic range of 5-2000 ng/mL for hydroxychloroquine in human blood, with coefficient of determination (r<sup>2</sup>
) of =0.9999. The values for intra-day and inter-day precisions of hydroxychloroquine were ≤7.86% with the accuracies ranged from 93.8% to 107.6%. The chromatographic run time was 3 min, making it possible to achieve a high throughput analysis. This method was used as a bio-analytical tool in a phase 1 clinical trial to quantify blood hydroxychloroquine concentrations in patients with non-small cell lung cancer receiving both hydroxychloroquine and gefitinib in their treatment.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0731-7085</s0>
</fA01>
<fA02 i1="01"><s0>JPBADA</s0>
</fA02>
<fA03 i2="1"><s0>J. pharm. biomed. anal.</s0>
</fA03>
<fA05><s2>61</s2>
</fA05>
<fA08 i1="01" i2="1" l="ENG"><s1>Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>WANG (Ling-Zhi)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ONG (Rina Yue-Ling)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CHIN (Tan-Min)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>THUYA (Win-Lwin)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>WAN (Seow-Ching)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>WONG (Andrea Li-Ann)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>CHAN (Sui-Yung)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>HO (Paul C.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>GOH (Boon-Cher)</s1>
</fA11>
<fA14 i1="01"><s1>Cancer Science Institute of Singapore, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Haematology & Oncology, The National University Health System</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>86-92</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>19962</s2>
<s5>354000508487210130</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0147418</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of pharmaceutical and biomedical analysis</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A novel and specific liquid chromatography-tandem mass spectrometric method (LC-MS/MS) was developed and validated for the quantification of hydroxychloroquine in human blood using its stable labeled isotope, hydroxychloroquine-d4 as the internal standard. Chromatographic separation of analytes was achieved using an Agilent ZORBAX Eclipse XDB - C8 analytical HPLC column (50 mm x 2.1 mm, 5 μm). The mobile phase comprising water containing 0.1% formic acid-acetonitrile (94:6, v/v) was delivered isocratically at a flow rate of 0.5 mL/min. The column effluent was detected by API 4000 triple quadrupole mass spectrometer using electrospray ionization (ESI) and monitored by multiple reaction monitoring with positive mode. The precursor to product ion transitions of m/z 336 → 247 and m/z 340 → 251 were used to measure the analyte and IS, respectively. The assay demonstrated a good linear dynamic range of 5-2000 ng/mL for hydroxychloroquine in human blood, with coefficient of determination (r<sup>2</sup>
) of =0.9999. The values for intra-day and inter-day precisions of hydroxychloroquine were ≤7.86% with the accuracies ranged from 93.8% to 107.6%. The chromatographic run time was 3 min, making it possible to achieve a high throughput analysis. This method was used as a bio-analytical tool in a phase 1 clinical trial to quantify blood hydroxychloroquine concentrations in patients with non-small cell lung cancer receiving both hydroxychloroquine and gefitinib in their treatment.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02A02</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Développement</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Development</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Desarrollo</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Validation</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Validation</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Validación</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Analyse quantitative</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Quantitative analysis</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Análisis cuantitativo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Hydroxychloroquine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Hydroxychloroquine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hidroxicloroquina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Human</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Liquide biologique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Biological fluid</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Líquido biológico</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Sang</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Blood</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Sangre</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Chromatographie HPLC</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>HPLC chromatography</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Cromatografía HPLC</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Spectrométrie masse tandem</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Mass spectrometry MS/MS</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Espectrometría masa en tándem</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Antiparasitaire</s0>
<s5>23</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Parasiticide</s0>
<s5>23</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Antiparasitario</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Antipaludique</s0>
<s5>24</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Antimalarial</s0>
<s5>24</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Antipalúdico</s0>
<s5>24</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Antirhumatismal</s0>
<s5>25</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Antirheumatic agent</s0>
<s5>25</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Antireumático</s0>
<s5>25</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>LC MS MS</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fN21><s1>114</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 12-0147418 INIST</NO>
<ET>Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry</ET>
<AU>WANG (Ling-Zhi); ONG (Rina Yue-Ling); CHIN (Tan-Min); THUYA (Win-Lwin); WAN (Seow-Ching); WONG (Andrea Li-Ann); CHAN (Sui-Yung); HO (Paul C.); GOH (Boon-Cher)</AU>
<AF>Cancer Science Institute of Singapore, National University of Singapore/Singapour (1 aut., 3 aut., 4 aut., 5 aut., 9 aut.); Department of Pharmacy, National University of Singapore/Singapour (2 aut., 7 aut., 8 aut.); Department of Haematology & Oncology, The National University Health System/Singapour (3 aut., 6 aut., 9 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of pharmaceutical and biomedical analysis; ISSN 0731-7085; Coden JPBADA; Pays-Bas; Da. 2012; Vol. 61; Pp. 86-92; Bibl. 25 ref.</SO>
<LA>Anglais</LA>
<EA>A novel and specific liquid chromatography-tandem mass spectrometric method (LC-MS/MS) was developed and validated for the quantification of hydroxychloroquine in human blood using its stable labeled isotope, hydroxychloroquine-d4 as the internal standard. Chromatographic separation of analytes was achieved using an Agilent ZORBAX Eclipse XDB - C8 analytical HPLC column (50 mm x 2.1 mm, 5 μm). The mobile phase comprising water containing 0.1% formic acid-acetonitrile (94:6, v/v) was delivered isocratically at a flow rate of 0.5 mL/min. The column effluent was detected by API 4000 triple quadrupole mass spectrometer using electrospray ionization (ESI) and monitored by multiple reaction monitoring with positive mode. The precursor to product ion transitions of m/z 336 → 247 and m/z 340 → 251 were used to measure the analyte and IS, respectively. The assay demonstrated a good linear dynamic range of 5-2000 ng/mL for hydroxychloroquine in human blood, with coefficient of determination (r<sup>2</sup>
) of =0.9999. The values for intra-day and inter-day precisions of hydroxychloroquine were ≤7.86% with the accuracies ranged from 93.8% to 107.6%. The chromatographic run time was 3 min, making it possible to achieve a high throughput analysis. This method was used as a bio-analytical tool in a phase 1 clinical trial to quantify blood hydroxychloroquine concentrations in patients with non-small cell lung cancer receiving both hydroxychloroquine and gefitinib in their treatment.</EA>
<CC>002B02A02; 002A02</CC>
<FD>Développement; Validation; Analyse quantitative; Hydroxychloroquine; Homme; Liquide biologique; Sang; Chromatographie HPLC; Spectrométrie masse tandem; Antiparasitaire; Antipaludique; Antirhumatismal; LC MS MS</FD>
<ED>Development; Validation; Quantitative analysis; Hydroxychloroquine; Human; Biological fluid; Blood; HPLC chromatography; Mass spectrometry MS/MS; Parasiticide; Antimalarial; Antirheumatic agent</ED>
<SD>Desarrollo; Validación; Análisis cuantitativo; Hidroxicloroquina; Hombre; Líquido biológico; Sangre; Cromatografía HPLC; Espectrometría masa en tándem; Antiparasitario; Antipalúdico; Antireumático</SD>
<LO>INIST-19962.354000508487210130</LO>
<ID>12-0147418</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000011 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000011 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:12-0147418
   |texte=   Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry

Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri